Blog

A firm touting itself as “Britain’s first psychedelic healthcare fund” has launched with the intention to invest more than £10 million ($13.5 million) in psychedelic focused companies.  Neo Kuma Ventures will fund what it believes are “the most exciting, high quality and scientifically sound players in the industry.” The fund has previously invested in atai Life Sciences, Beckley Psytech, and Brightminds. The fund’s founders are: Clara Burtenshaw, a 35-year old lawyer Sean McLintock, a 30-year old entrepreneur who founded a CBD drinks company Drink Three Dots Nick David, who will lead Investor Relations With much of the current investments occurring…

Tryp Therapeutics Inc. announced the successful closing of its previously announced initial public offering.

Numinus Wellness Inc. has completed the first legal extraction of Psilocybe mushrooms in Canada by a public company for research and development purposes.

Global biotech company atai Life Sciences, which is developing psychedelic compounds for mental health, today announced the appointment of a new Chief Medical Officer (CMO) and Chief Financial Officer (CFO) in preparation for an upcoming Initial Public Offering (IPO). Greg Weaver and Rolando Gutierrez-Esteinou have joined atai as CFO and CMO, respectively. Greg Weaver, who previously joined atai as a consulting CFO in July 2020, has now assumed a permanent position as of September 2020. Greg has over 25 years of Chief Financial Officer and board director experience focusing on taking startup biotech companies through clinical development and commercial offerings….

Ehave, Inc. announced KetaDASH, an Intravenous (IV) based, home delivery platform for patients who have been prescribed Ketamine.